Exclusive Summary

• Targets the massive prostate cancer and endometriosis markets with high technological barriers in microsphere formulation, resulting in very few generic competitors globally and providing a distinct blue-ocean advantage.
• API strictly complies with USP and EP premium standards, significantly accelerating regulatory approvals and mitigating registration risks for local distributors globally.
• Listed as a WHO Essential Medicine and NCCN first-line therapy (ADT), providing guaranteed clinical demand and generating substantial profit margins for originator substitution through robust supply-chain cost advantages.